Al Hammadi Holding Releases Results for the Quarter Ended 31 March 2025

12 May 2025, Riyadh (Saudi Arabia). Al Hammadi Holding ("Al Hammadi", the "Company", or the "Group"), an owner and operator of premier medical facilities in Saudi Arabia, announces its financial and operational results for the quarter ended 31 March 2025 (Q1 2025). The Company reported revenues of SAR 302 million in Q1 2025, up a solid 9% year-on-year (y-o-y) despite the anticipated slowdown associated with Ramadan weighing on patient traffic throughout the entire month of March. Similarly, net profit came in at SAR 74 million in Q1 2025, increasing by 15% versus Q1 2024, and yielding a net profit margin (NPM) of 24%, up from the 23% margin recorded in Q1 2024.

Key Financial and Operational Highlights

Financial Highlights (SAR mn)	Q4 2024	Q-o-Q Change	Q1 2024	Q1 2025	Y-o-Y Change
Total Revenues	322.8	*-6.5%*	277.0	301.9	*9.0%*
Cost of Sales	(213.2)	*-3.7%*	(186.0)	(205.4)	*10.4%*
Gross Profit	**109.6**	***-12.0%***	**91.1**	**96.5**	***6.0%***
GPM	34.0%	*-2.0pts*	32.9%	32.0%	*-0.9pts*
Operating Profit	**78.6**	***-2.4%***	**74.9**	**76.7**	***2.4%***
Operating Profit Margin	24.4%	*1.1pts*	27.0%	25.4%	*-1.6pts*
Net Profit	**77.8**	***-4.9%***	**64.0**	**73.9**	***15.4%***
NPM	24.1%	*0.4pts*	23.1%	24.5%	*1.4pts*
Operational Highlights ('000)					
Inpatient Volumes	11.7	*-3.2%*	*10.0*	11.3	*13.3%*
Outpatient Volumes	274.2	*-8.6%*	*249.5*	250.7	*0.5%*

- Al Hammadi reported **total revenues** of SAR 302 million in Q1 2025, up 9% y-o-y, primarily driven by strong top-line growth at both the Group's medical services and pharmaceutical segments. Revenues from medical services came in at SAR 241 million in Q1 2025, up 6% y-o-y supported by Al Nuzha hospital's solid 11% y-o-y growth. Revenue growth was also supported by a solid 23% y-o-y increase in revenues from pharmaceuticals, fueled by an 8% y-o-y increase from the Group's in-house pharmacies, along with increasing sales at Pharma Serve following the Group's strategic decision to expand its offering to private sector clients.
- The Group's top-line performance was further supported by **growing volumes** at both the inpatient and outpatient segments which returned to year-on-year growth in line with the Group's expectations and despite the full month of Ramadan occurring during the first quarter this year.
- **Net profit** for Q1 2025 reached SAR 74 million, a 15% y-o-y increase, with NPM expanding by one percentage point to 24%, up from 23% in Q1 2024. Improved net profitability reflects the Group's continued efforts to maintain a tight grip on costs coupled with increased finance income during the quarter as well as rising contributions from Sudair Pharmaceuticals (SPC) where insulin production started in 2024.
- **Net cash to equity** recorded 5.3% as at 31 March 2025 compared to 3.1% at year-end 2024.

- **Inpatient admissions** reached 11.3 thousand in Q1 2025, up 13% y-o-y driven by robust rises in inpatient volumes at both Al Nuzha and Al Suweidi.
- **Outpatient visits** increased by 0.5% in Q1 2025 to reach 250.7 thousand. Average revenue per outpatient visit also grew 6% y-o-y, in line with the Group's long-term multi-phase growth strategy.

Management Comment

As we step into 2025, which marks Al Hammadi Holding's 40th anniversary, I am pleased to report that the Group has delivered a robust first quarter performance in line with our expectations and long-term growth ambitions. Our first quarter results reflect the strength of our diversified business model and the successful execution of our growth initiatives. During the first three months of the year, we were very pleased to see both our medical services and pharmaceutical segments contribute to top-line growth, highlighting the robust growth momentum enjoyed across our diversified offering. In alignment with our long-term vision, we have recently taken the first step towards further expanding our offering to cover the entirety of our patients' treatment journey, with the signing of a non-binding memorandum of understanding with Wareed Medical. The potential investment would see us acquire a 40% stake in a leading diagnostics services provider, marking our official entrance in Riyadh's highly fragmented, and currently underserved diagnostics market. We are very excited about this opportunity, and we look forward to providing the latest updates on the deal as they arise over the coming months.

Turning to our results, during the first quarter the Group delivered impressive 9% year-on-year top-line growth, with revenue for the quarter surpassing the SAR 300 million mark. Growth was primarily supported by increased patient volumes, in particular at our inpatient segment, which grew despite the anticipated slowdown associated with the holy month of Ramadan weighing on traffic during the entire month of March. The solid results posted during the quarter fuel our optimism heading into the spring and summer months and further validate the effectiveness of our multi-stage growth strategy rolled out at the beginning of last year. During the quarter, revenue from the insurance segment reached a record-high of SAR 208 million, up a solid 7% versus the previous year supported by both strategic price adjustments and higher volumes. Our proactive pivot towards insurance patients comes as rising competition from newly inaugurated long-term care facilities is expected to weigh on revenue from MOH referrals throughout the coming year. Further down the income statement, we recorded marginal year-on-year compressions in both our gross and operating margins reflecting mainly higher salary and wage expenses on the back of annual compensation adjustments and new staff hires. Despite this, we continue to be pleased with the Group-wide efforts to optimise spending and boost operational efficiencies, and we are confident that our work on this front will support an improvement in profitability going forward. Meanwhile, we reported a robust 15% year-on-year expansion in bottom-line, with its associated margin rising to 24% for the quarter.

On the capacity expansion front, we remain on track to meet our longer-term targets. Over the coming five years, we are aiming to bring online 600 new inpatient rooms and 360 new outpatient clinics across three world-class facilities located in high-potential neighborhoods of Riyadh. Our plans to more than double our existing capacity are aligned with the ambitious vision of the Saudi Arabian government which will see Riyadh's population continue to grow over the coming decade. Across our hospitals, we are also developing new centers of excellence focused on advanced medical specialties, further reinforcing our market position and reputation as Riyadh's leading provider of premium healthcare.

Beyond our core hospital business, it is important to mention that Sudair Pharmaceuticals (SPC), where we hold a 35% stake, continues to make solid progress on its expansion roadmap. Building on the work done last year, which saw the company launch the first phase of its insulin production line and make significant strides in developing new respiratory medicines, in February 2025, SPC officially kicked off construction at its insulin production line's second phase. These strategic moves support our mission to facilitate access to critical treatments, diversify revenue streams, and proactively contribute to the Kingdom's vision of becoming a regional pharmaceutical hub.

As we progress through 2025, our priorities remain unchanged. During the first phase of our new growth strategy rolled out last year, we are primarily focused on implementing strategic price adjustments across our service portfolio as we work to realize our premiumization ambitions while ensuring we are well placed to benefit from the introduction of the new Diagnostic Related Groups (DRGs) classification system in 2027. Further ahead, our focus will shift towards volume-driven growth, as we leverage the previously mentioned capacity expansions and the expected growth in demand coming from Riyadh's fast-growing and increasingly health-conscious population.

As we celebrate four decades of excellence, we remain focused on delivering long-term value through innovation, operational excellence, and patient-centered care. With a clear roadmap and a solid foundation, Al Hammadi is well-positioned to lead the next chapter of growth in the Kingdom's healthcare sector.

Mohammad S. Al Hammadi
Chief Executive Officer

Consolidated Analysis







Financial Review

Revenue Analysis

Al Hammadi posted total revenues of SAR 302 million in Q1 2025, up 9% versus Q1 2024, driven by higher revenues from both medical services and pharmaceuticals. Revenue growth during the quarter was supported by rising patient volumes, highlighting the sustained demand for its value-driven services.

Medical Services (80% of total revenue in Q1 2025)

Medical services, which include inpatient and outpatient operations at both Al Nuzha and Al Suwaidi hospitals, reported revenue of SAR 241 million in Q1 2025, up 6% y-o-y. Medical services accounted for 80% of the Company's consolidated top-line during the first quarter down from 82% in Q1 2024.

- On a by **hospital** basis, Al Nuzha posted a solid 11% y-o-y increase in revenue in Q1 2025. Top-line growth at the facility was supported by increasing volumes at both inpatient and outpatient segments, reflecting the anticipated normalization post-price adjustments. Meanwhile, Al Suwaidi's revenue marginally declined by 1% y-o-y, owing to a 2% y-o-y decrease in outpatient admissions which outweighed a 6% y-o-y increase in average revenue per outpatient visit.
- On a **patient**-type basis, the Group's top-line performance was supported by a 7% y-o-y increase in insurance revenue, primarily on the back of higher average revenue per insurance patient. Revenue from both cash and MoH patients returned to year-on-year growth as the high base effects which had weighed on the segments' growth rates over the course of 2024 subsided.
- Finally, on a **segmental** basis, at the inpatient segment, revenues grew 5% y-o-y to reach SAR 125 million, on the back of an impressive 13% y-o-y increase in inpatient volumes. Similarly, outpatient revenues recorded a 7% y-o-y rise, primarily supported by a 6% y-o-y rise in average revenue per outpatient, coupled with a modest 0.5% y-o-y increase in outpatient volumes.

Meanwhile, Al Hammadi posted a 6% q-o-q decline in revenues during Q1 2025, reflecting the anticipated slowdown in patient traffic linked to Ramadan. It is also worth noting that results in Q4 2024 had included a SAR 8 million boost following the implementation of new government regulations related to the treatment of non-eligible foreign patients. Going

Al Hammadi Holding

Medical Services Revenue by Patient Type (Q1 2025)



Gross Profit, GPM (SAR mn, %)



Net Profit, Margin (SAR mn, %)



forward, the Group will continue to bill the MOH once a year in December for the treatment of this patient subsegment

Pharmaceutical Services (20% of total revenue in Q1 2025)

Meanwhile, Al Hammadi's pharmaceutical sales contributed 20% of consolidated revenue, recording SAR 61 million for Q1 2025, a 23% y-o-y increase. During the quarter, Al Hammadi's in-house pharmacies (located in Al Nuzha and Al Suwaidi) generated sales of SAR 50 million, up 8% y-o-y from Q1 2024, capturing higher traffic across both hospitals, as patient volumes across the two facilities returned to solid year-on-year growth. Meanwhile, Pharma Serve booked sales of SAR 11 million in Q1 2025, up from the SAR 3 million recorded this time last year, reflecting the company's strategic decision to expand its service offering to private sector clients. Pharma Serve had previously only taken part in government tenders.

Cost of Revenue

Al Hammadi's cost of revenue stood at SAR 205 million for Q1 2025, up 10% y-o-y from the SAR 186 million recorded in Q1 2024. As a share of total revenue, cost of revenue remained largely stable at 68%, as a year-on-year increase in salary and wage expenses was partially offset by Group-wide efforts to optimize spending and boost operational efficiencies.

Gross Profit

Gross profit recorded SAR 97 million, a 6% y-o-y increase from Q1 2024. Gross profit margin recorded 32% in Q1 2025 down just one percentage point from the previous year and remaining largely in line with gross margins recorded over the past year.

Sales, general & administrative (SG&A)

SG&A expenses recorded SAR 26 million, up 9% from the SAR 25 million recorded in Q1 2024. As a share of revenue, SG&A outlays remained stable at 9% for the quarter. Increasing SG&A costs came on the back of higher marketing spending for the quarter as part of the Group's strategy to boost its brand visibility and service offering awareness.

Operating Profit

Operating profit recoded SAR 77 million in Q1 2025, up 2% versus the SAR 75 million booked in Q1 2024. Meanwhile, the Group's operating margin contracted by two percentage points to reach 25% for Q1 2025. Operating profit for the quarter also captures a SAR 0.3 million expected credit loss provision reversal reflecting the successful settlement of claims related to 2024.

Net Profit

Al Hammadi reported a net profit of SAR 74 million during Q1 2025, up 15% from Q1 2024. Net profit margin expanded by one percentage point to 24% versus 23% in Q1 2024. During the quarter, Al Hammadi booked a 27% year-on-year decline in net finance costs owing to higher finance income as a result of increased cash balances for the period. The Group also recorded SAR 5 million in profits from subsidiaries as SPC ramps up production.

Dividend Payments

Al Hammadi adheres to a clear **dividend** policy of distributing no less than 60% of annual profits on a quarterly basis to shareholders. In light of the strong results consistently delivered and the business's positive outlook, the Company has announced the distribution of a SAR 56 million cash dividend for the first quarter of 2025.

Balance Sheet Highlights

Al Hammadi's **total assets** stood at SAR 2,667 million as at 31 March 2025, up from SAR 2,651 million as of year-end 2024. **Inventories** as at 31 March 2025 booked SAR 72 million, up from SAR 61 million as at year-end 2024. Rising inventories are related to the Group's growing pharmaceutical operations.

Cash and cash equivalents booked SAR 291 million as of 31 March 2025, up from SAR 245 million as of 31 December 2024. The Company's current and quick ratios recorded 3.5 and 3.2, respectively, in line with FY 2024.

The Company recorded **total debt** of SAR 186 million as of 31 March 2025, versus SAR 184 million as of year-end 2024. Total debt is wholly made up of zero-interest government grants. Meanwhile, the company recorded a **net cash balance** of SAR 105 million as at 31 March 2025, versus SAR 61 million as at 31 December 2024.

Shareholders' equity posted SAR 1,980 million as of 31 March 2025, increasing from the SAR 1,961 million recorded as of 31 December 2024. The Company recorded debt/equity of approximately 9.4% as of 31 March 2025, unchanged from year-end 2024. Additionally, net cash to equity came in at 5.3% as at 31 March 2025, versus 3.1% at the close of FY 2024.

Operational Review



Inpatient Volumes

On a Group level, Al Hammadi recorded **inpatient admissions** of 11,304 during Q1 2025, representing a 13% y-o-y increase, driven by increasing inpatient volumes at both Al Nuzha and Al Suwaidi. During the quarter, Al Nuzha hospital recorded a 16% y-o-y rise in inpatient admission and contributed to 63% of total inpatient admissions, up from the 61% contribution made in Q1 2024. Meanwhile, Al Suwaidi hospital, which accounted for the remaining 37% of inpatient admissions during the quarter, saw admission volumes rise 8% versus the same three months of last year. It is worth nothing that the quarter-on-quarter decline in inpatient admissions is attributable to the anticipated slowdown in patient traffic across both facilities during the holy month of Ramadan which commenced on 1 March this year as opposed to 11 March last year.



Outpatient Volumes

Al Hammadi recorded 250,667 outpatient visits during Q1 2025, up 0.5% compared to Q1 2024. This growth is mainly attributable to higher patient traffic at Al Nuzha hospital. This reflects a gradual recovery in patient activity which continues to normalize following the strategic price adjustments and is expected to accelerate further as new capacity additions ramp up. During the quarter, outpatient volumes posted a 9% q-o-q decrease compared to Q4 2024, reflecting the above-mentioned temporary slowdown in activity associated with Ramadan. The Company's Al Nuzha facility accounted for 63% of all outpatient examinations in Q1 2025, up from 62% in Q1 2024. Contributions from Al Suwaidi hospital stood at 37% in Q1 2025 compared to 38% in the corresponding three-month period of last year.

Utilization

Throughout Q1 2025, Al Hammadi reported improving utilization rates across both its hospitals and patient segments. At the inpatient segment, Al Nuzha recorded an average utilization rate of 90% in Q1 2025, while Al Suwaidi's utilization rate across its operational beds (currently 180 beds) registered 100%, reflecting the transfer of MoH patients from Al Nuzha starting in Q4 2024. Similarly, across the Group's outpatient clinics, utilization at both Al Nuzha and Al Suweidi hospitals reached 90% during Q1 2025.

Sudair Pharma Company (SPC)

SPC, a leading pharmaceutical manufacturer in which Al Hammadi holds a 35% stake, continues to move forward with its planned operational upgrades and product launches. Established in 2014, the company has been focused on producing oncology medications since 2021. Recently, SPC initiated the first phase of its insulin production line, with construction of phase two commencing in February 2025. Additionally, SPC is expanding its portfolio with plans to launch new respiratory-focused medications.

Capacity Expansions

On the **capacity expansion** front, the Company continues to make significant strides as it works to deliver on its ambitious long- and short-term growth strategies.

In the **short term**, Al Hammadi has focused on expanding inpatient and outpatient capacity across its two existing facilities. Over the past three years, the Company has launched 20 new inpatient rooms at Al Suwaidi Hospital and 20 new outpatient clinics at Al Nuzha Hospital. Additionally, in 2024 it introduced expanded working hours across its outpatient clinics going from eight to 12 hours while also opening them up to treat patients on Fridays. These expansions have increased the Group's total capacity to 600 inpatient rooms and 220 outpatient clinics, enabling it to effectively meet the growing demand for high-quality healthcare in Riyadh.

In parallel, Al Hammadi is advancing its **long-term** growth strategy, aiming to launch three new facilities by 2030. More specifically, construction work at the Olaya facility officially began in June 2024, with the relaunch set for 2026. Olaya will house 200 inpatient rooms and 120 outpatient clinics, as well as two centers of excellence specializing in sports medicine and oncology. The second facility, Al Narjis, is slated for inauguration in the first quarter of 2028 and will also house 200 inpatient rooms, 120 outpatient clinics, as well as two centers of excellence specializing in rehabilitation and plastic surgery. Construction work at Al Hammadi's fourth hospital (Al Narjis) is scheduled to begin later in 2025 and be completed in around 30 months. Finally, the Group successfully acquired a new plot of land in Riyadh's Al Mansiyah district in November 2024, intended for the construction of its fifth hospital. Al Mansiyah facility will have the same capacity as its two new facilities, featuring 200 new inpatient rooms and 120 new clinics, and will enable the Group to tap into North Riyadh's underserved market. These expansions will see the Group more than double its bed capacity within the coming six years, strengthening the Company's market position in Riyadh's competitive healthcare market. CAPEX expenditures to fuel the Group's growth strategy over the coming three years (2025 to 2027) are earmarked in the range of SAR 550 million.

– End –

Consolidated Income Statement

SAR mn	Q4 2024	Q-o-Q Change	Q1 2024	Q1 2025	Y-o-Y Change
Revenue	**322.8**	***(6.5%)***	**277.0**	**301.9**	***9.0%***
Cost of revenue	(213.2)	*(3.7%)*	(186.0)	(205.4)	*10.4%*
Gross Profit	**109.6**	***(12.0%)***	**91.1**	**96.5**	***6.0%***
GPM	34.0%	*-2.0ppt*	32.9%	32.0%	*-0.9ppt*
Selling and marketing expenses	0.3	*(833.9%)*	(0.7)	(2.5)	*230.2%*
Administrative and general expenses	(25.5)	*(7.5%)*	(24.3)	(23.6)	*-2.9%*
Expected credit loss provision	(12.9)	*(102.6%)*	2.2	0.3	*(84.8%)*
Impairment loss in intangible assets	-		-	-	-
Gain (Loss) on disposal of property, plant and equipment	-		-	-	-
Other operating income	7.1	*(16.4%)*	6.7	6.0	*(11.5%)*
Operating Profit	**78.6**	***(2.4%)***	**74.9**	**76.7**	***2.4%***
Operating profit margin	24.4%	*1.1ppt*	*27.0%*	25.4%	*-1.6ppt*
Share of profit in subsidiaries	2.8	*93.6%*	0.0	5.5	*N/A*
Finance income	2.2	*(8.4%)*	-	2.0	-
Finance costs	(6.0)	*4.3%*	(5.9)	(6.3)	*7.4%*
Net profit before Zakat	**77.6**	***0.4%***	**69.0**	**77.9**	***12.9%***
Zakat expenses	0.1	*(3405.0%)*	(5.0)	(4.0)	*(20.0%)*
Net profit for the period	**77.8**	***(4.9%)***	**64.0**	**73.9**	***15.4%***
NPM	24.1%	*0.4ppt*	*23.1%*	24.5%	*1.4ppt*
	-		-	-	
Earnings per share:	0.49	*-4.9%*	0.40	0.46	***15.4%***

Consolidated Balance Sheet

SAR mn	31 December 2024	31 March 2025
ASSETS		
Non-current assets		
Property and equipment	1,709.5	1,689.9
Intangible assets and goodwill	27.1	27.1
Investment in associates	135.0	140.4
Total non-current assets	**1,871.6**	**1,857.4**
Current Assets		
Inventories	61.2	72.3
Other receivables	7.2	9.0
Prepayments	21.9	25.3
Contract assets	9.1	7.6
Trade receivables	434.4	405.0
Cash and cash equivalents	245.3	290.9
Total current assets	**779.1**	**810.1**
TOTAL ASSETS	**2,650.7**	**2,667.5**
SHAREHOLDER'S EQUITY AND LIABILITIES		
SHAREHOLDER'S EQUITY		
Share capital	1,600.0	1,600.0
General reserve	101.2	101.2
Retained earnings	260.0	279.3
TOTAL SHAREHOLDER'S EQUITY	**1,961.2**	**1,980.5**
LIABILITIES		
Non-current liabilities		
Loans	165.1	157.6
Government grants	98.0	96.4
Lease liabilities	104.1	104.9
Employees' terminal benefits	97.4	98.1
Total non-current liabilities	**464.6**	**457.0**
Current liabilities		
Loans	18.7	28.6
Government grants	7.8	7.2
Lease liabilities	16.2	16.1
Accrued zakat	15.5	4.0
Trade payables	66.4	59.7
Accrued expenses	53.7	53.6
Other payables	16.0	20.7
Contract liabilities	30.6	40.1
Total current liabilities	**224.9**	**230.0**
TOTAL LIABILITIES	**689.5**	**687.0**
TOTAL SHAREHOLDER'S EQUITY AND LIABILITIES	**2,650.7**	**2,667.5**

Consolidated Statement of Cash Flow

SAR mn	31 March 2024	31 March 2025
OPERATING ACTIVITIES		
Net profit	64.0	73.9
Adjustments to reconcile net profit to cash flow		
Depreciation of property and equipment	22.9	20.8
Depreciation of ROU asset's	2.8	2.8
Amortization of intangible assets	0.2	0.1
Company share of profits from associate	(0.0)	(5.5)
Provision for expected credit losses	(2.2)	(0.3)
Government grants released	(2.3)	(2.3)
Current services cost of employees' terminal benefits	3.6	2.2
Contract liability generated during the period	11.4	18.2
Finance income	-	(2.0)
Finance cost	5.9	6.3
Zakat charge during the period	5.0	4.0
	111.3	118.2
Working capital adjustments		
Inventories	(0.8)	(11.1)
Other debit balances	(0.5)	(1.1)
Prepayments	(1.6)	(3.3)
Trade receivables	52.9	30.0
Contract assets	1.2	1.5
Due from (to) related parties- net	(3.8)	(0.2)
Accounts payable	(11.7)	(7.3)
Accrued expenses	1.9	(0.3)
Other credit balances	(4.3)	4.3
Contract liability	(0.0)	(8.7)
Employees' terminal benefits paid	(1.7)	(1.3)
Zakat paid	-	(15.5)
NET CASH GENERATED FROM OPERATING ACTIVITIES	**142.9**	**105.2**
INVESTING ACTIVITIES		
Purchase of property and equipment	(5.9)	(3.9)
Purchase of intangible assets	(0.1)	(0.2)
Finance income received	-	1.3
NET CASH USED IN INVESTING ACTIVITIES	**(6.0)**	**(2.8)**
FINANCING ACTIVITIES		
Finance charges paid	(0.4)	(0.6)
Lease liability	-	(0.6)
Dividends paid	(55.7)	(55.6)
NET CASH USED IN FINANCING ACTIVITIES	**(56.1)**	**(56.8)**
Net change in cash and cash equivalents	80.8	45.6
Cash and cash equivalents at the beginning of the period	125.2	245.3
CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD	**206.0**	**290.9**

About Al Hammadi Holding

Al Hammadi Holding is an integrated healthcare company and a premier hospital operator in Riyadh providing world-class healthcare services to hundreds of thousands of local and foreign residents each year. The company currently operates two hospitals in the Saudi Arabian capital, housing more than 600 inpatient rooms and 220 outpatient clinics. In line with the company's ambitious growth plans and Saudi Arabia's Vision 2030 strategy, Al Hammadi is aiming to inaugurate three more facilities in Riyadh over the coming six years, more than doubling its inpatient and outpatient capacity. Al Hammadi also offers retail pharmacy services through a network of physical stores and a growing online presence and is also active in the vaccine import segment through its subsidiary, Pharma Serve. Al Hammadi boasts several international accreditations and certificates, including the Canadian Accreditation Certificate (ACCREDITATION CANADA), the Joint Commission International (JCI) accreditation, the Australian Council on Healthcare Standards International (ACHSI), the Saudi Central Board for Accreditation of Healthcare Institutions (CBAHI), the American College of Cardiology (ACC) accreditation, as well as the ISO 9001:2008 certification and the Saudi Heart Association Certificate.

Contact

Investor Relations Department
ir@alhammadi.com